ARTICLE | Emerging Company Profile
Hybridize: kidney-targeted RNA therapeutics
With backing from biotech vets Maraganore, van de Stolpe, Dutch newco is building a platform of kidney-targeted RNA therapies
July 14, 2022 10:03 PM UTC
After out-licensing its first kidney program, Leiden University Medical Center spinout Hybridize is now building a platform to improve the uptake and activity of RNA-based therapies in specific kidney cells, with the goal of reducing inflammation and fibrosis.
“There’s a white space in the area of RNA therapeutics for the kidney,” CEO Eline van Beest told BioCentury...